EVERSPIN TECHNOLOGIES INC. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data EVERSPIN TECHNOLOGIES INC. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	27.1	35.9	49.4	37.5	42	55.1	60	63.8	50.4	55.2
Cost of revenue	12.4	14.5	24.1	19.2	23.9	22.1	26	26.5	24.3	27
Gross profit	14.7	21.5	25.3	18.3	18.1	33.1	33.9	37.2	26.1	28.2
Research and development	19.2	25.4	23.6	14.2	10.9	12.6	11.1	11.8	13.7	14.1
Selling and marketing	3.71	4.74	6.47	5.36	3.98	4.46	4.87	5.29	5.39	6.11
General and administrative	7.28	11.5	12.6	12.4	10.8	10.9	11.7	14.3	14.1	14.6
Operating expenses	30.2	41.7	42.7	32.7	25.7	28	27.7	31.4	33.2	34.8
Operating income	-15.5	-20.2	-17.3	-14.4	-7.56	5.04	6.23	5.89	-7.09	-6.51
Interest expense	2.35	0.76	0.89	0.75	0.67	0.55	0.27	0.06
Interest income									1.77	1.65
Other non-operating income	1.16	0.12	0.46	0.49	-0.02	-0.14	0.19	3.21	6.07	4.41
Pre-tax income				-14.7	-8.25	4.35	6.14	9.04	0.74	-0.46
Income tax	0	0	0	0	0.26	0	0.01	-0.02	-0.04	0.13
Net income	-16.7	-21.1	-17.8	-14.7	-8.51	4.34	6.13	9.05	0.78	-0.59
EBITDA	-14.7	-19	-15.9	-12.7	-5.58	6.49	7.21	7.09	-5.36	-3.3
EPS, basic	-3.53	-1.69	-1.08	-0.85	-0.45	0.22	0.30	0.44	0.04	-0.03
EPS, diluted	-3.53	-1.69	-1.08	-0.85	-0.45	0.22	0.29	0.42	0.04	-0.03
Shares, basic (weighted)	5.12	12.6	16.4	17.3	18.8	19.4	20.1	20.7	21.6	22.6
Shares, diluted (weighted)	4.74	12.5	16.4	17.3	18.8	20	20.8	21.4	22.2	22.6
Dividend per share	0.00	0.00		0.00	0.00	0.00	0.00	0.00	0.00	0.00

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	29.7	13	23.4	14.5	14.6	21.4	26.8	36.9	42.1	44.5
Receivables	3.17	4.04	7.52	5.8	7.61	8.19	10.7	11.6	11.7	8.1
Inventory	5.07	9.84	9.1	7.86	5.72	6.4	6.68	8.39	9.11	10.7
Other current assets	1.05	0.59	0.69	0.54	0.27	0.76	0.6	0.99	1.27	1.88
Total current assets	39.5	27.4	40.7	28.7	28.2	36.8	44.7	57.9	64.2	65.2
Property, plant and equipment	1.92	3.95	4.29	3.48	1.95	0.97	3.88	3.72	3.22	14.1
Lease right-of-use assets				3.13	2.31	0.91	6.64	5.5	4.55	3.25
Intangible assets									3.42	1.71
Other non-current assets	0.05	0.07	0.07	0.07	0.07	0.73	0.06	0.21	2.4	0.34
Total assets	41.5	31.4	45	35.4	32.5	39.4	55.3	67.3	77.8	84.6
Accounts payable	1.5	2.92	2.64	2.87	2.22	1.78	2.78	2.92	2.28	5.18
Accrued liabilities	1.81	3.75	5	2.73	2.23	3.58	3.53	4.34	2.45	3.65
Deferred revenue	1.83	1.72				0.83	0.82	0.34	0.08	0
Short-term debt	3.88	3.99	5.98	0.67	4.24	3.37	2.59		1.77	1.77
Total current liabilities	10.4	12.4	13.6	7.89	10.2	10.3	10.9	8.78	9.91	13.5
Long-term debt	4.22	8.18	6.51	7.15	3.75	1.53			1.78	0.02
Lease liabilities				1.84	0.9	0.07
Total liabilities	14.6	20.6	20.1	16.9	15.1	12.1	16.7	13.4	15.2	15.7
Total debt	8.1	12.2	12.5	7.82	7.99	4.9	2.59		3.55	1.78
Paid-in capital	123	128	159	167	175	180	185	192	199	206
Retained earnings	-96.4	-118	-134	-149	-157	-153	-147	-138	-137	-137
Shareholders' equity	26.9	10.9	24.9	18.5	17.4	27.2	38.7	53.9	62.6	68.9
Total equity	26.9	10.9	24.9	18.5	17.4	27.2	38.7	53.9	62.6	68.9
Total liabilities and equity	41.5	31.4	45	35.4	32.5	39.4	55.3	67.3	77.8	84.6
Shares outstanding	12.5	12.8	17.1	18.1	19	19.9	20.4	21.1	22.1	23

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-16.7	-21.1	-17.8	-14.7	-8.51	4.34	6.13	9.05	0.78	-0.59
Depreciation and amortization	0.83	1.19	1.45	1.69	1.98	1.46	0.98	1.21	1.73	3.21
Stock-based compensation	1.14	2.05	2.67	3.55	3.97	3.23	4.41	5.01	6.71	5.78
Deferred income tax								-0.15	-0.13	0.12
Change in receivables	-1.26	-0.39	-3.82	1.72	-1.81	-0.59	-2.47	-0.89	-0.17	3.62
Change in inventory	-0.89	-3.87	0.69	1.23	2.14	-0.68	-0.29	-1.71	-0.72	-1.62
Change in payables	0.34	0.81	-0.18	0.2	-0.82	-0.57	0.56	0.5	-0.37	-0.5
Cash from operations	-18.5	-18.9	-14.7	-8.12	-2.92	9.36	9.49	13.1	7.1	9.96
Capital expenditures	-1.04	-3.07	-1.91	-0.86	-0.32	-1.03	-2.79	-1.4	-3.05	-6.84
Cash from investing	-1.04	-3.07	-1.91	-0.86	-0.32	-1.03	-2.59	-1.39	-3.06	-8.67
Debt issued	1.5	12	1
Debt repaid	-1.33	-8.36	-1	-4.84		-3.4	-2.4	-2.79
Stock issued	0.05		24.5
Cash from financing	47	5.18	27	0.09	3.36	-1.52	-1.52	-1.59	1.11	1.07
Net change in cash	27.4	-16.8	10.4	-8.89	0.11	6.81	5.39	10.2	5.15	2.35
Free cash flow	-19.6	-22	-16.6	-8.98	-3.24	8.33	6.71	11.7	4.05	3.12
Interest paid	0.81	0.47	0.5	0.48	0.34	0.23	0.17	0.04
Income taxes paid			0.03	0.05					0.2	0.04

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $18.47 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	52.3%	Gross profit / revenue.
Operating margin	-15.5%	Operating income / revenue.
EBITDA margin	-10.9%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	-4.0%	Pre-tax income / revenue.
Net margin	-4.2%	Net income / revenue.
FCF margin	-8.6%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	6.8%	Cash from operations / revenue.
Return on equity (ROE)	-3.6%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-2.9%	Net income / average total assets.
Return on invested capital (ROIC)	-25.5%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	25.0%	Research and development expense / revenue.
Stock-based pay / revenue	8.7%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	15.4%	Capital expenditures / revenue.
D&A / revenue	4.7%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	9.5%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	-2.7%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	5.6%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	8.1%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	-5.9%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	9.3%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	-175.0%	Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y	-175.0%	EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y	40.3%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	1.6%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow growth, 1y	-22.9%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	-22.5%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y	10.1%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	21.2%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	31.7%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	8.8%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	15.2%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	21.1%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	1.9%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	2.8%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	3.7%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	4.74x	Current assets / current liabilities.
Quick ratio	3.75x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	3.01x	(Cash + short-term investments) / current liabilities.
Debt / equity	0.01x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	1.0%	Total debt / total assets.
Liabilities / assets	18.2%	Total liabilities / total assets.
Net debt	-$43.0M	Total debt - cash - short-term investments. Negative means more cash than debt.
Working capital	$54.4M	Current assets - current liabilities.
Goodwill and intangibles / assets	1.0%	(Goodwill + intangible assets) / total assets.
Tangible book value	$72.2M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.70x	Revenue / average total assets.
Fixed asset turnover	4.21x	Revenue / average property, plant and equipment.
Inventory turnover	2.28x	Cost of revenue / average inventory.
Days inventory	160 days	365 x average inventory / cost of revenue.
Receivables turnover	5.80x	Revenue / average receivables.
Days sales outstanding	63 days	365 x average receivables / revenue.
Days payables	29 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	194 days	Days inventory + days sales outstanding - days payables.
Capex / operating cash flow	227.1%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$0.11	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$2.62	Revenue / diluted weighted shares.
FCF per share	-$0.23	Free cash flow / diluted weighted shares.
Operating cash flow per share	$0.18	Cash from operations / diluted weighted shares.
Book value per share	$3.01	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$2.98	Tangible book value / shares outstanding.
Cash per share	$1.81	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$449.7M	Share price x shares outstanding.
Enterprise value	$406.8M	Market cap + total debt - cash - short-term investments.
P/S	7.20x	Market cap / revenue.
P/B	6.15x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	6.23x	Market cap / tangible book value, when positive.
P/OCF	106x	Market cap / cash from operations, when positive.
EV/Sales	6.51x	Enterprise value / revenue.
FCF yield	-1.2%	Free cash flow / market cap.
Earnings yield	-0.6%	Net income / market cap (the inverse of P/E).

What was EVERSPIN TECHNOLOGIES INC.'s revenue in fiscal 2025?

EVERSPIN TECHNOLOGIES INC. reported revenue of $55.2M for fiscal 2025, 9.5% higher than the year before.

Was EVERSPIN TECHNOLOGIES INC. profitable in fiscal 2025?

No. It reported a net loss of $586.0K.

How much free cash flow did EVERSPIN TECHNOLOGIES INC. generate in fiscal 2025?

Cash from operations of $10.0M minus capital expenditures of $6.8M left free cash flow of $3.1M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to EVERSPIN TECHNOLOGIES INC.